Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43DC.A.TO 0.3NESN-SIX 0MCK 31.3
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Apr 27, 2006
Owns Teva (TEVA-Q) as a growth stock and owns this one as a value stock. This one seems to be doing things correctly, more so than Merk (MRK-N). Feels the environment has bottomed out and will be getting better. Low risk.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.86

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 30, 2006
Likes the pharmaceutical sector. This one is very cheap. Dividend of 3.5%. Trading at 10 X earnings.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.20

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 21, 2006
The fundamental outlook is improving. The worst is behind it. The company is swimming in cash. There could be another dividend increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.31

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2006
Pfizer is a large cap pharma. Probably the largest pharma company in the world. Has suffered along with the rest of the industry. It is well positioned. Very attractive. Good dividend yield. Predicts it will continue to grow 12-15%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$25.95

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Feb 28, 2006
Developed a new inhalant insulin product. Good product as diabetes continue to grow. They have had some litigation problems and some patents will be expiring. Worth watching it.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$26.19

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Feb 24, 2006
They need to do some building of pipeline, so the stock will be going sideways for awhile, but there will be demand.
Photo of David DriscollDavid DriscollUnlock Rating
$26.14

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2006
He likes this industry. The growth is not what it used to be. Evaluations are cheaper than they have been in a long time. Growth stocks are cheaper than they have been in last 20 years.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$26.19

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 14, 2006
It's in their top 10 of their US-value 50. It's currently below what he paid for it.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$25.50

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2006
(A Top Pick Dec 5/05. Up 20%.) They got a positive legal ruling on Lipator which protects their patent. They increased their dividend. Have just announced that they will be doing something with their consumer product division, spinning out to shareholders or selling it.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.58

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 02, 2006
This is a value stock and is showing up under his parameters as a buy. As a strategic investor, this would be the time to buy this.
Photo of Jim O'ShaughnessyJim O'Shaughnessy
Owned
Unlock Rating
$25.78

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 31, 2006
Thinks the heyday of those large pharmaceutical companies have come and gone. The pipeline is relatively bare. They have reached a point in time when they are trying to cut costs at a greater rate than the revenue decline. Not a good business to be in at this point.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$25.68

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 20, 2006
4% dividend yield. Trades had about 11 X earnings. They should continue to do well.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.71

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 28, 2005
Uses a two-pronged approach. Teva (TEVA-Q) is his growth drug stock and Pfizer (PFE-N) is his value drug stock. Thinks the tide has turned for this stock. Just won the Lipitor patent case giving them patent protection through to 2011. Have upped their dividend.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.60

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 22, 2005
Big pharmaceuticals have just been decimated this year. This one just won a major patent challenge in the last few days, so the sentiment has turned a bit. It will take some time for these stocks to give the kind of return that we were used to. Still phenomenally profitable. Very cheap, trading at 11 X earnings. Good dividend.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$24.06

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 13, 2005
He has a 2-pronged approach to the pharmaceutical area. Has a growth segment through Teva (TEVA-Q) and this one is his value play. Dividend is now about 4.5%. It’s selling at about 12/13 X next year’s earnings. Have a great pipeline coming along.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.31

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 631 to 645 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.86$313.26
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.71$53.29
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.79$96.32
U.U.TO 0.5$20.92
SII.TO 2.94$190.13
IPCO.TO -0.43$34.79

Popular Articles

Latest Sell Signals

RKLB -1.37$66.91
INTC 0.22$87.48
MSFT 4.4$491.71
WSP.TO -2.98$189.3
CLS.TO 16.21$423.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like